Drugs / Wharton jelly derived mesenchymal stem cells
Wharton jelly derived mesenchymal stem cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT05413148 Comparator | Aug 2022 → Jul 2023 | retinitis pigmentosa | TC Erciyes University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Wharton jelly derived mesenchymal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05413148 ↗ |
| Modality | Cell therapy | “Wharton jelly-derived mesenchymal stem cells” NCT05413148 ↗ |
| Route | Other | “Single subtenon's injection for single eye” NCT05413148 ↗ |